Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Bearish
3
Neutral
4
Bullish
7
Bearish
22
Neutral
4
Bullish
20
Bearish
19
Neutral
0
Bullish
13
Discovery themes featuring this stockDiscovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
341.90 | 1,006 Cr | 14.02 | 2.47 | 1.07 | 17.67 | 20.02 | 10.84 | ||
292.00 | 983 Cr | 62.36 | 1.84 | 0.00 | 8.81 | 10.79 | 1.71 | ||
106.45 | 971 Cr | 851.93 | 2.66 | 0.00 | 0.42 | 2.70 | 0.19 | ||
265.75 | 929 Cr | 21.61 | 12.00 | 0.00 | 51.51 | 27.98 | 10.39 | ||
1335.00 | 913 Cr | -111.52 | 2.83 | 0.08 | -2.54 | -1.83 | -4.45 | ||
183.05 | 886 Cr | 34.41 | 1.67 | 1.64 | 4.85 | 6.56 | 2.83 | ||
690.25 | 813 Cr | 21.99 | 2.32 | 0.07 | 10.54 | 16.04 | 7.98 | ||
| Median: 7 Co. | — | 292.00 | 929 Cr | 21.99 | 2.47 | 0.07 | 8.81 | 10.79 | 2.83 |
Wanbury Limited specializes in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and formulations. It holds a significant global market share in products such as Metformin and Sertraline, establishing robust leadership in these key therapeutic categories.
The company has successfully undergone an operational and financial turnaround over the last two years, transitioning towards growth momentum and de-risked financial structures, with a notable reduction in debt levels and borrowing costs.
Wanbury has fortified its market presence with established global regulatory approvals, including USFDA and ANVISA, enhancing its credibility and access to developed markets.
Recent advances in the API business include the launch of new anaesthetic drugs and plans for 4 new molecule commercializations annually, focusing on high-value and large-volume market opportunities.
The company's business strategy emphasizes building its formulations and API brands, focusing on new therapeutic launches and geographic expansion, while deploying digital transformations for enhanced operational efficiencies.
Pharmaceuticals & Biotechnology
Pharmaceuticals
929 Cr
High Risk
21.6
34.1
-0.9
12.0
329.00
162.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Wanbury Ltd (WANBURY) is currently trading at 259.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Wanbury Limited specializes in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and formulations. It holds a significant global market share in products such as Metformin and Sertraline, establishing robust leadership in these key therapeutic categories. The company has successfully undergone an operational and financial turnaround over the last two years, transitioning towards growth momentum and de-risked financial structures, with a notable reduction in debt levels and borrowing costs. Wanbury has fortified its market presence with established global regulatory approvals, including USFDA and ANVISA, enhancing its credibility and access to developed markets. Recent advances in the API business include the launch of new anaesthetic drugs and plans for 4 new molecule commercializations annually, focusing on high-value and large-volume market opportunities. The company's business strategy emphasizes building its formulations and API brands, focusing on new therapeutic launches and geographic expansion, while deploying digital transformations for enhanced operational efficiencies.
Over the past 52 weeks, Wanbury Ltd has traded between a low of ₹162.00 and a high of ₹329.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Wanbury Ltd has a market capitalization of approximately 929.04. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Wanbury Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 929.04 Cr, Wanbury Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Wanbury Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Wanbury Ltd is 21.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Regulatory Compliance
Wanbury's Tanuku API site completed Australia's TGA quality inspection; issuance of the GMP certificate will allow shipment of three additional APIs; Patalganga site recently received MFDS (Korean FDA) GMP certification for its April 2026 inspection.
Regulatory Submission
Wanbury announced regulatory submissions to launch new APIs: DMFs for Diphenhydramine HCl filed in Malaysia and Singapore, proposed DMFs for Paroxetine HCl for Korea and Latin America, and a Korea MFDS audit of Patalganga facility with zero observations.
